[1]
|
Piccini, J. and Allen, L. (2017) Heart Failure Complicated by Atrial Fibrillation: Don’t Bury the Beta-Blockers Just Yet. JACC: Heart Failure, 5, 107-109. https://doi.org/10.1016/j.jchf.2016.12.003
|
[2]
|
Benjamin, E., Muntner, P., Alonso, A., et al. (2019) Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Associa-tion. Circulation, 139, e56-e528. https://doi.org/10.1161/CIR.0000000000000659
|
[3]
|
Santhanakrishnan, R., Wang, N., Larson, M., et al. (2016) Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation, 133, 484-492.
https://doi.org/10.1161/CIRCULATIONAHA.115.018614
|
[4]
|
Heidenreich, P., Albert, N., Allen, L., et al. (2013) Forecasting the Impact of Heart Failure in the United States: A Policy Statement from the American Heart Association. Circulation Heart Failure, 6, 606-619.
https://doi.org/10.1161/HHF.0b013e318291329a
|
[5]
|
Raunsø, J., Pedersen, O., Dominguez, H., et al. (2010) Atri-al Fibrillation in Heart Failure Is Associated with an Increased Risk of Death Only in Patients with Ischaemic Heart Dis-ease. European Journal of Heart Failure, 12, 692-697.
https://doi.org/10.1093/eurjhf/hfq052
|
[6]
|
Sata, N., Hamada, N., Horinouchi, T., et al. (2004) C-Reactive Protein and Atrial Fibrillation. Is Inflammation a Consequence or a Cause of Atrial Fibrillation? Japanese Heart Journal, 45, 441-445.
https://doi.org/10.1536/jhj.45.441
|
[7]
|
Zhang, Z., Yu, Y., Kang, Y., Wei, S. and Felder, R.B. (2008) Aldosterone Acts Centrally to Increase Brain Renin-Angiotensin System Activity and Oxidative Stress in Normal Rats. American Journal of Physiology: Heart and Circulatory Physiology, 294, H1067-H1074. https://doi.org/10.1152/ajpheart.01131.2007
|
[8]
|
Ren, X., Zhang, F., Zhao, M., et al. (2017) Angiotensin-(1-7) in Paraventricular Nucleus Contributes to the Enhanced Cardiac Sympathetic Afferent Reflex and Sympathetic Activity in Chronic Heart Failure Rats. Cellular Physiology and Biochemistry, 42, 2523-2539. https://doi.org/10.1159/000480214
|
[9]
|
Chen, P.-S., Chen, L.S., Fishbein, M.C., Lin, S.-F. and Nattel, S. (2014) Role of the Autonomic Nervous System in Atrial Fibrillation: Pathophysiology and Therapy. Circulation Research, 114, 1500-1515.
https://doi.org/10.1161/CIRCRESAHA.114.303772
|
[10]
|
Burashnikov, A. and Antzelevitch, C. (2003) Reinduction of Atrial Fibrillation Immediately after Termination of the Arrhythmia Is Mediated by Late Phase 3 Early Afterdepolariza-tion-Induced Triggered Activity. Circulation, 107, 2355-2360. https://doi.org/10.1161/01.CIR.0000065578.00869.7C
|
[11]
|
Kim, S.-M., Kim, J.-M., Shin, D.-G., Kim, J.-R. and Cho, K.-H. (2014) Relation of Atrial Fibrillation (AF) and Change of Lipoproteins: Male Patients with AF Exhibited Se-vere Pro-Inflammatory and Pro-Atherogenic Properties in Lipoproteins. Clinical Biochemistry, 47, 869-875. https://doi.org/10.1016/j.clinbiochem.2013.10.026
|
[12]
|
Sonmez, O., Ertem, F., Vatankulu, M., et al. (2014) Novel Fibro-Inflammation Markers in Assessing Left Atrial Remodeling in Non-Valvular Atrial Fibrillation. Medical Science Monitor, 20, 463-470.
https://doi.org/10.12659/MSM.890635
|
[13]
|
Bukowska, A., Schild, L., Keilhoff, G., et al. (2008) Mitochondrial Dysfunction and Redox Signaling in Atrial Tachyarrhythmia. Experimental Biology and Medicine, 233, 558-574. https://doi.org/10.3181/0706-RM-155
|
[14]
|
Kim, S., Lee, J., Kim, J., et al. (2011) Female Patients with Atrial Fi-brillation Have Increased Oxidized and Glycated Lipoprotein Properties and Lower Apolipoprotein A-I Expression in HDL. International Journal of Molecular Medicine, 27, 841-849. https://doi.org/10.3892/ijmm.2011.646
|
[15]
|
Dharmarajan, K. and Dunlay, S. (2016) Multimorbidity in Older Adults with Heart Failure. Clinics in Geriatric Medicine, 32, 277-289. https://doi.org/10.1016/j.cger.2016.01.002
|
[16]
|
Hassanein, M., Abdelhamid, M., Ibrahim, B., et al. (2015) Clinical Characteristics and Management of Hospitalized and Ambulatory Patients with Heart Failure-Results from ESC Heart Failure Long-Term Registry-Egyptian Cohort. ESC Heart Failure, 2, 159-167. https://doi.org/10.1002/ehf2.12046
|
[17]
|
Aleong, R., Sauer, W., Davis, G. and Bristow, M.R. (2014) New-Onset Atrial Fibrillation Predicts Heart Failure Progression. The American Journal of Medicine, 127, 963-971. https://doi.org/10.1016/j.amjmed.2014.06.006
|
[18]
|
Mitchell, J., Tam, S., Trivedi, K., et al. (2011) Atrial Fibrillation and Mortality in African American Patients with Heart Failure: Results from the African American Heart Failure Trial (A-HeFT). American Heart Journal, 162, 154-159. https://doi.org/10.1016/j.ahj.2011.04.022
|
[19]
|
Olesen, J., Lip, G., Lindhardsen, J., et al. (2011) Risks of Thromboembolism and Bleeding with Thromboprophylaxis in Patients with Atrial Fibrillation: A Net Clinical Benefit Analysis Using a “Real World” Nationwide Cohort Study. Thrombosis and Haemostasis, 106, 739-749. https://doi.org/10.1160/TH11-05-0364
|
[20]
|
Vinereanu, D., Stevens, S., Alexander, J., et al. (2015) Clinical Outcomes in Patients with Atrial Fibrillation According to Sex during Anticoagulation with Apixa-ban or Warfarin: A Secondary Analysis of a Randomized Controlled Trial. European Heart Journal, 36, 3268-3275. https://doi.org/10.1093/eurheartj/ehv447
|
[21]
|
Otto, C. (2017) Heartbeat: Healthcare Approaches to Reducing Ad-verse Outcomes in Patients with Atrial Fibrillation. Heart, 103, 1925-1927. https://doi.org/10.1136/heartjnl-2017-312538
|
[22]
|
Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. (2014) Com-parison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Me-ta-Analysis of Randomised Trials. The Lancet, 383, 955-962. https://doi.org/10.1016/S0140-6736(13)62343-0
|
[23]
|
Kirchhof, P., Benussi, S., Kotecha, D., et al. (2016) 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. EP Europace, 18, 1609-1678. https://doi.org/10.1093/europace/euw295
|
[24]
|
Hindricks, G., Potpara, T., Dagres, N., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the Eu-ropean Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal, 42, 373-498. https://doi.org/10.1093/eurheartj/ehaa612
|
[25]
|
Vamos, M., Erath, J.W., Benz, A.P., Lopes, R.D. and Hohnloser, S.H. (2019) Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. The American Journal of Cardiology, 123, 69-74. https://doi.org/10.1016/j.amjcard.2018.09.036
|
[26]
|
Cadrin-Tourigny, J., Shohoudi, A., Roy, D., et al. (2017) De-creased Mortality with Beta-Blockers in Patients with Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. JACC: Heart Failure, 5, 99-106.
https://doi.org/10.1016/j.jchf.2016.10.015
|
[27]
|
Gitt, A., Smolka, W., Michailov, G., et al. (2013) Types and Out-comes of Cardioversion in Patients Admitted to Hospital for Atrial Fibrillation: Results of the German RHYTHM-AF Study. Clinical Research in Cardiology, 102, 713-723. https://doi.org/10.1007/s00392-013-0586-x
|
[28]
|
Hobbs, W., Fynn, S., Todd, D., et al. (2000) Reversal of Atrial Electrical Remodeling after Cardioversion of Persistent Atrial Fibrilla-tion in Humans. Circulation, 101, 1145-1151. https://doi.org/10.1161/01.CIR.101.10.1145
|
[29]
|
Airaksinen, K., Grönberg, T., Nuotio, I., et al. (2013) Thromboembolic Complications after Cardioversion of Acute Atrial Fibrillation: The FinCV (Finnish CardioVersion) Study. Journal of the American College of Cardiology, 62, 1187-1192. https://doi.org/10.1016/j.jacc.2013.04.089
|
[30]
|
Hansen, M., Jepsen, R., Olesen, J., et al. (2015) Thromboembolic Risk in 16,274 Atrial Fibrillation Patients Undergoing Direct Current Cardioversion with and without Oral Anticoagulant Therapy. EP Europace, 17, 18-23.
https://doi.org/10.1093/europace/euu189
|
[31]
|
Brignole, M., Botto, G., Mont, L., et al. (2011) Cardiac Resynchro-nization Therapy in Patients Undergoing Atrioventricular Junction Ablation for Permanent Atrial Fibrillation: A Ran-domized Trial. European Heart Journal, 32, 2420-2429. https://doi.org/10.1093/eurheartj/ehr162
|
[32]
|
January, C.T., Wann, L.S., Calkins, H., et al. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiolo-gy/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation, 140, e125-e151. https://doi.org/10.1161/CIR.0000000000000665
|
[33]
|
Packer, D., Mark, D., Robb, R., et al. (2019) Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA, 321, 1261-1274. https://doi.org/10.1001/jama.2019.0693
|
[34]
|
Marrouche, N., Brachmann, J., Andresen, D., et al. (2018) Catheter Ablation for Atrial Fibrillation with Heart Failure. The New England Journal of Medicine, 378, 417-427. https://doi.org/10.1056/NEJMoa1707855
|
[35]
|
Di Biase, L., Burkhardt, J., Mohanty, P., et al. (2010) Left Atrial Appendage: An Underrecognized Trigger Site of Atrial Fibrillation. Circulation, 122, 109-118. https://doi.org/10.1161/CIRCULATIONAHA.109.928903
|
[36]
|
Dar, T., Afzal, M., Yarlagadda, B., et al. (2018) Mechanical Function of the Left Atrium Is Improved with Epicardial Ligation of the Left Atrial Appendage: Insights from the LAFIT-LARIAT Registry. Heart Rhythm, 15, 955-959.
https://doi.org/10.1016/j.hrthm.2018.02.022
|
[37]
|
Reddy, V., Doshi, S., Kar, S., et al. (2017) 5-Year Outcomes af-ter Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. Journal of the American College of Cardiology, 70, 2964-2975.
https://doi.org/10.1016/j.jacc.2017.10.021
|
[38]
|
Sulke, N., Silberbauer, J., Boodhoo, L., et al. (2007) The Use of Atrial Overdrive and Ventricular Rate Stabilization Pacing Algorithms for the Prevention and Treatment of Paroxysmal Atrial Fibrillation: The Pacemaker Atrial Fibrillation Suppression (PAFS) Study. EP Europace, 9, 790-797. https://doi.org/10.1093/europace/eum111
|
[39]
|
Tehrani, D., Adatya, S., Grinstein, J., et al. (2019) Impact of Cardiac Resynchronization Therapy on Left Ventricular Unloading in Patients with Implanted Left Ventricular Assist Devices. ASAIO Journal, 65, 117-122.
https://doi.org/10.1097/MAT.0000000000000787
|
[40]
|
Yancy, C., Jessup, M., Bozkurt, B., et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Founda-tion/American Heart Association Task Force on Practice Guidelines. Circulation, 128, e240-e327. https://doi.org/10.1161/CIR.0b013e31829e8776
|
[41]
|
Gasparini, M., Steinberg, J., Arshad, A., et al. (2010) Re-sumption of Sinus Rhythm in Patients with Heart Failure and Permanent Atrial Fibrillation Undergoing Cardiac Resyn-chronization Therapy: A Longitudinal Observational Study. European Heart Journal, 31, 976-983. https://doi.org/10.1093/eurheartj/ehp572
|
[42]
|
Priori, S. and Blomström-Lundqvist, C. (2015) 2015 European Soci-ety of Cardiology Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Summarized by Co-Chairs. European Heart Journal, 36, 2757-2759. https://doi.org/10.1093/eurheartj/ehv316
|
[43]
|
Lu, T., Yang, B., Wang, R. and Qin, C. (2019) Xenotransplantation: Current Status in Preclinical Research. Frontiers in Immunology, 10, Article 3060. https://doi.org/10.3389/fimmu.2019.03060
|